PD-L1、B7-H3及B7-H4在宫颈癌免疫治疗中的研究进展

doi:10.12280/gjfckx.20201027

摘要/Abstract

摘要：

宫颈癌是我国常见的妇科恶性肿瘤,其发生和发展常与免疫逃逸有关,免疫治疗已经成为目前宫颈癌治疗的研究热点。随着免疫检查点程序性死亡配体1（PD-L1）及程序性死亡受体1（PD-1）的抑制剂在多种恶性肿瘤中的成功应用,以PD-L1为代表的共刺激因子与宫颈癌的研究愈发受到关注,其中负性共刺激因子与宫颈癌免疫抑制密切相关。PD-L1即B7-H1,与B7-H3和B7-H4都属于常见的负性共刺激因子,其通过抑制免疫反应,使癌细胞发生免疫逃逸。许多研究显示PD-L1、B7-H3和B7-H4在宫颈癌中异常高表达,抑制了对宫颈癌细胞的免疫应答,在宫颈癌的发生发展、侵袭转移和预后等方面具有相应的临床意义。对负性共刺激因子PD-L1、B7-H3和B7-H4的生物学功能以及在宫颈癌中的表达和应用进展进行综述,以期为宫颈癌的免疫靶向治疗提供新思路。

关键词: 共刺激因子, 宫颈肿瘤, PD-L1, B7-H3, B7-H4, 免疫疗法

Abstract:

Cervical cancer is a common gynecological malignancies in China. Its occurrence and development are often related to immune escape. Immunotherapy has become a research hotspot in the treatment of cervical cancer. With the successful application of immune checkpoint programmed death 1 ligand (PD-L1) and programmed death 1 (PD-1) inhibitors in a variety of malignant tumors, the study of costimulatory factors represented by PD-L1 and cervical cancer has attracted more and more attention, among which negative costimulatory factors are closely related to the immunosuppression of cervical cancer. PD-L1, namely B7-H1, is a common negative costimulatory factor along with B7-H3 and B7-H4, which causes immune escape of cancer cells by inhibiting the immune response. Many studies have shown that PD-L1, B7-H3 and B7-H4 are abnormally high expressed in cervical cancer, which inhibits the immune response to cervical cancer cells, and has corresponding clinical significance in the development, invasion, metastasis and prognosis of cervical cancer. This paper reviewed the biological functions of negative costimulatory factors PD-L1, B7-H3 and B7-H4, as well as their expression and application in cervical cancer, in order to provide a new idea for the immunotargeted therapy of cervical cancer.

Key words: Co-stimulator, Uterine cervical neoplasms, PD-L1, B7-H3, B7-H4, Immunotherapy

苏雅婷, 吕杰, 牛雯娟, 魏芳. PD-L1、B7-H3及B7-H4在宫颈癌免疫治疗中的研究进展[J]. 国际妇产科学杂志, 2021, 48(4): 457-461.

SU Ya-ting, LYU Jie, NIU Wen-juan, WEI Fang. Research Progress of PD-L1, B7-H3 and B7-H4 in Immunotherapy of Cervical Cance[J]. Journal of International Obstetrics and Gynecology, 2021, 48(4): 457-461.

参考文献 32

[1]	黄成琳, 张淑兰. 负性共刺激因子B7-H4在宫颈癌中的研究进展[J]. 国际妇产科学杂志, 2016, 43(4):432-435.
[2]	金正宇, 古彦铮, 赵鑫, 等. 负性共刺激分子在胆囊癌中的表达及其临床意义[J]. 临床与实验病理学杂志, 2019, 35(11):1354-1357. doi: 10.13315/j.cnki.cjcep.2019.11.022. doi: 10.13315/j.cnki.cjcep.2019.11.022
[3]	Qi ZJ, Yu D, Chen CH, et al. The prognostic value of B7H1 and B7H4 expression in pancreatic cancer: A meta-analysis[J]. Int J Biol Markers, 2019, 34(4):373-380. doi: 10.1177/1724600819881147. doi: 10.1177/1724600819881147
[4]	Li Y, Cui N, Zheng PS, et al. BMX/Etk promotes cell proliferation and tumorigenicity of cervical cancer cells through PI3K/AKT/mTOR and STAT3 pathways[J]. Oncotarget, 2017, 8(30):49238-49252. doi: 10.18632/oncotarget.17493. doi: 10.18632/oncotarget.17493
[5]	Wang Y, Li G. PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives[J]. Front Med, 2019, 13(4):438-450. doi: 10.1007/s11684-018-0674-4. doi: 10.1007/s11684-018-0674-4
[6]	耿卫朴. 人乳腺癌中共刺激分子PD-L1、PD-L2的表达及其临床意义[J]. 临床与实验病理学杂志, 2017, 33(1):59-62. doi: 10.13315/j.cnki.cjcep.2017.01.015. doi: 10.13315/j.cnki.cjcep.2017.01.015
[7]	陈宏伟, 徐怡顺. B7-H1在甲状腺乳头状癌组织中的表达及其临床意义[J]. 中国医师杂志, 2018, 20(2):235-237. doi: 10.3760/cma.j.issn.1008-1372.2018.02.020. doi: 10.3760/cma.j.issn.1008-1372.2018.02.020
[8]	吴璨, 翟志敏, 吴凡, 等. B7-H1通过调节肿瘤免疫微环境促进AML肿瘤细胞免疫逃逸的实验研究[J]. 临床肿瘤学杂志, 2020, 25(6):494-499. doi: 10.3969/j.issn.1009-0460.2020.06.003. doi: 10.3969/j.issn.1009-0460.2020.06.003
[9]	Noman MZ, Janji B, Abdou A, et al. The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200[J]. Oncoimmunology, 2017, 6(1):e1263412. doi: 10.1080/2162402X.2016.1263412. doi: 10.1080/2162402X.2016.1263412
[10]	Han S, Shi X, Liu L, et al. Roles of B7-H3 in Cervical Cancer and Its Prognostic Value[J]. J Cancer, 2018, 9(15):2612-2624. doi: 10.7150/jca.24959. doi: 10.7150/jca.24959
[11]	李艺. B7-H3在宫颈癌发展中作用的研究[D]. 济南:山东大学, 2017.
[12]	Chapoval AI, Ni J, Lau JS, et al. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production[J]. Nat Immunol, 2001, 2(3):269-274. doi: 10.1038/85339. doi: 10.1038/85339 pmid: 11224528
[13]	Zhang X, Ji J, Zhang G, et al. Expression and significance of B7-H3 and Tie-2 in the tumor vasculature of clear cell renal carcinoma[J]. Onco Targets Ther, 2017, 10:5417-5424. doi: 10.2147/OTT.S147041. doi: 10.2147/OTT.S147041
[14]	Lee YH, Martin-Orozco N, Zheng P, et al. Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function[J]. Cell Res, 2017, 27(8):1034-1045. doi: 10.1038/cr.2017.90. doi: 10.1038/cr.2017.90
[15]	Han S, Li Y, Zhang J, et al. Roles of immune inhibitory molecule B7-H4 in cervical cancer[J]. Oncol Rep, 2017, 37(4):2308-2316. doi: 10.3892/or.2017.5481. doi: 10.3892/or.2017.5481
[16]	马迪, 马文超, 唐芳兰, 等. 共刺激分子B7-H4在宫颈癌组织中的表达及其临床意义[J]. 中国计划生育和妇产科, 2018, 10(4):45-48,52. doi: 10.3969/j.issn.1674-4020.2018.04.11. doi: 10.3969/j.issn.1674-4020.2018.04.11
[17]	Wang W, Xu C, Wang Y, et al. Prognostic values of B7-H4 in non-small cell lung cancer[J]. Biomarkers, 2016:1-16. doi: 10.1080/1354750X.2016.1203997. doi: 10.1080/1354750X.2016.1203997
[18]	祁紫娟, 于丹, 周照旭, 等. 探讨共刺激分子PD-L1、PD-L2和B7-H4在宫颈癌中的表达及病理特征研究[J]. 中国农村卫生, 2019, 11(16):88-89. doi: 10.3969/j.issn.1674-361X.2019.16.101. doi: 10.3969/j.issn.1674-361X.2019.16.101
[19]	Tao J, Dai J, Hou S. Association between B7-H1 and cervical cancer: B7-H1 impairs the immune response in human cervical cancer cells[J]. Exp Ther Med, 2017, 14(5):4125-4133. doi: 10.3892/etm.2017.5100. doi: 10.3892/etm.2017.5100
[20]	Barquín-García A, Molina-Cerrillo J, Garrido P, et al. New oncologic emergencies: What is there to know about inmunotherapy and its potential side effects?[J]. Eur J Intern Med, 2019, 66:1-8. doi: 10.1016/j.ejim.2019.05.020. doi: S0953-6205(19)30178-5 pmid: 31130304
[21]	Gong J, Chehrazi-Raffle A, Reddi S, et al. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations[J]. J Immunother Cancer, 2018, 6(1):8. doi: 10.1186/s40425-018-0316-z. doi: 10.1186/s40425-018-0316-z pmid: 29357948
[22]	Chung HC, Ros W, Delord JP, et al. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study[J]. J Clin Oncol, 2019, 37(17):1470-1478. doi: 10.1200/JCO.18.01265. doi: 10.1200/JCO.18.01265
[23]	Zhen S, Lu J, Liu YH, et al. Synergistic antitumor effect on cervical cancer by rational combination of PD1 blockade and CRISPR-Cas9-mediated HPV knockout[J]. Cancer Gene Ther, 2020, 27(3/4):168-178. doi: 10.1038/s41417-019-0131-9. doi: 10.1038/s41417-019-0131-9
[24]	Zheng Y, Yang Y, Wu S, et al. Combining MPDL3280A with adoptive cell immunotherapy exerts better antitumor effects against cervical cancer[J]. Bioengineered, 2017, 8(4):367-373. doi: 10.1080/21655979.2016.1230573. doi: 10.1080/21655979.2016.1230573 pmid: 27754760
[25]	吴进锋, 何毅辉, 林乐, 等. B7-H3和PD-L1在肾细胞癌组织中的表达及临床意义[J]. 福建医药杂志, 2020, 42(2):16-20. doi: 10.3969/j.issn.1002-2600.2020.02.005. doi: 10.3969/j.issn.1002-2600.2020.02.005
[26]	Zuo J, Wang B, Long M, et al. The type 1 transmembrane glycoprotein B7-H3 interacts with the glycolytic enzyme ENO1 to promote malignancy and glycolysis in HeLa cells[J]. FEBS Lett, 2018, 592(14):2476-2488. doi: 10.1002/1873-3468.13164. doi: 10.1002/1873-3468.13164
[27]	Chen L, Jin M, Li C, et al. The tissue distribution and significance of B7-H4 in laryngeal carcinoma[J]. Oncotarget, 2017, 8(54):92227-92239. doi: 10.18632/oncotarget.21152. doi: 10.18632/oncotarget.21152
[28]	Qiu F, Yuan C, Xu J, et al. Role of B7-H4 in the Progression and Prognosis of Cervical Inflammation to Cancer After Human Papilloma Virus Infection[J]. J Biomed Nanotechnol, 2019, 15(5):1043-1051. doi: 10.1166/jbn.2019.2741. doi: 10.1166/jbn.2019.2741
[29]	刘畅, 李坤, 舒丽莎, 等. B7-H4和Foxp3+ Treg在宫颈病变组织中的表达及临床意义[J]. 重庆医学, 2019, 48(17):2960-2963. doi: 10.3969/j.issn.1671-8348.2019.17.019. doi: 10.3969/j.issn.1671-8348.2019.17.019
[30]	Han S, Wang Y, Shi X, et al. Negative roles of B7-H3 and B7-H4 in the microenvironment of cervical cancer[J]. Exp Cell Res, 2018, 371(1):222-230. doi: 10.1016/j.yexcr.2018.08.014. doi: 10.1016/j.yexcr.2018.08.014
[31]	Han Q, Wang Y, Pang M, et al. STAT3-blocked whole-cell hepatoma vaccine induces cellular and humoral immune response against HCC[J]. J Exp Clin Cancer Res, 2017, 36(1):156. doi: 10.1186/s13046-017-0623-0. doi: 10.1186/s13046-017-0623-0
[32]	Zhang J, Liu L, Han S, et al. B7-H3 is related to tumor progression in ovarian cancer[J]. Oncol Rep, 2017, 38(4):2426-2434. doi: 10.3892/or.2017.5858. doi: 10.3892/or.2017.5858